ERBB2 and non-small cell lung carcinoma: In the ZENITH20‐2 trial, the ORR of poziotinib reached 27.8% [95% CI: 18.9%–38.2%], and the mPFS was 5.5 months [95% CI: 3.9–5.8 months] in previously treated patients with HER2 exon 20 insertion NSCLC.12